Additional file 6: of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

Vandenberghe, Rik; Rinne, Juha; Boada, Mercè; Katayama, Sadao; Scheltens, Philip; Vellas, Bruno; Tuchman, Michael; Gass, Achim; Fiebach, Jochen; Hill, Derek; Lobello, Kasia; Li, David; McRae, Tom; Lucas, Prisca; Evans, Iona; Booth, Kevin; Luscan, Gerald; Wyman, Bradley; Hua, Lisa; Yang, Lingfeng; Brashear, H.; Black, Ronald

doi:10.6084/m9.figshare.c.3603020_D5.v1

13195_2016_189_MOESM6_ESM.pdf (339.96 kB)

Additional file 6: of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

journal contribution

posted on 2016-05-12, 05:00 authored by Rik Vandenberghe, Juha Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens, Bruno Vellas, Michael Tuchman, Achim Gass, Jochen Fiebach, Derek Hill, Kasia Lobello, David Li, Tom McRae, Prisca Lucas, Iona Evans, Kevin Booth, Gerald Luscan, Bradley Wyman, Lisa Hua, Lingfeng Yang, H. Brashear, Ronald Black

List of independent ethics committees or institutional review boards. Complete list of independent ethics committees for all sites that screened subjects for the ApoE ε4 noncarrier study. (PDF 339 kb)

Funding

Pfizer Inc.

History

Usage metrics

Keywords

Alzheimer’s disease Bapineuzumab Immunotherapy Amyloid β Clinical trial ARIA-E Vasogenic edema

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 6: of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

Funding

Pfizer Inc.

History

Usage metrics

Categories

Keywords

Licence

Exports